A kind of tripterine/doxorubicin hydrochloride self-assembly nano-medicine and its preparation method and application
A technology of tripterine and doxorubicin hydrochloride, which is applied in the field of medicine, can solve the problems of heart and kidney toxicity and side effects that limit the clinical application of doxorubicin hydrochloride, and achieve good solid tumors with high permeability and retention, high yield, Effect of reducing toxicity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0058] The nanomedicine provided in this embodiment includes tripterine and doxorubicin hydrochloride, and the particle diameter of the nanomedicine is 90nm, and the hydrated particle diameter is 200nm.
[0059] The preparation method is as follows:
[0060] (1) 4.5mg tripterine was dissolved in 1mL dimethyl sulfoxide to obtain solution A whose molar concentration of tripterine was 10mM / L;
[0061] (2) Dissolve 5.8 mg of doxorubicin hydrochloride in 1 mL of deionized water to obtain a solution B with a molar concentration of doxorubicin hydrochloride of 10 mM / L;
[0062] (3) 100 μL of the solution A obtained in step (1) was injected into 800 μL of water three times, injected into deionized water, and magnetically stirred at a speed of 50 rpm at 20° C. to obtain solution C;
[0063] (4) 100 μL of solution B obtained in step (2) was injected into solution C obtained in step (3) and mixed to obtain solution D, which was magnetically stirred at 20° C. at a speed of 50 rpm for 24 ...
Embodiment 2
[0066] The nanomedicine provided in this embodiment includes tripterine and doxorubicin hydrochloride, and the nanomedicine has a particle size of 50 nm and a hydrated particle size of 100 nm.
[0067] The preparation method is as follows:
[0068] (1) 45mg tripterine was dissolved in 1mL methanol to obtain solution A;
[0069] (2) 29 mg of doxorubicin hydrochloride was dissolved in 1 mL of deionized water to obtain solution B;
[0070] (3) 10 μL of the solution A obtained in step (1) was injected into 890 μL of water for three times, injected into deionized water, and magnetically stirred at a speed of 2000 rpm at 40° C. to obtain solution C;
[0071] (4) 100 μL of solution B obtained in step (2) was injected into solution C obtained in step (3) and mixed to obtain solution D, which was magnetically stirred at 40° C. at a speed of 2000 rpm for 12 hours to obtain nanomedicine.
[0072] Detection of synthesized nanomedicines by fluorescence absorption spectroscopy, such as ...
Embodiment 3
[0074] The nanomedicine provided in this embodiment includes tripterine and doxorubicin hydrochloride, and the particle diameter of the nanomedicine is 80 nm, and the hydrated particle diameter is 105 nm.
[0075] The preparation method is as follows:
[0076] (1) 22.5mg tripterine was dissolved in 1mL dichloromethane to obtain solution A;
[0077] (2) Dissolve 0.58 mg of doxorubicin hydrochloride in 1 mL of deionized water to obtain solution B;
[0078] (3) 32 μL of the solution A obtained in step (1) was injected into 808 μL of water three times, injected into deionized water, and magnetically stirred at a speed of 500 rpm at 80° C. to obtain solution C;
[0079] (4) 160 μL of solution B obtained in step (2) was injected into solution C obtained in step (3) and mixed to obtain solution D, which was magnetically stirred at 80° C. at a speed of 500 rpm for 1 h to obtain nanomedicine.
[0080] Carry out dynamic light scattering test (DLS) to the nano-medicine provided in this...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More